Dermatology Times' Sunday Crossword: May 25, 2025

Welcome to Dermatology Times' Sunday Crossword, where dermatology knowledge meets fun! Each week, we curate a selection of words and terms pulled directly from the latest news in the dermatology world. Whether it's breakthrough treatments, new research findings, or emerging trends, this crossword serves as both a challenge and an opportunity to reinforce your expertise in the field.

This week, we're focusing on insights from our digital chronic hand eczema (CHE) supplement. To learn more, including to view and download the supplement for exclusive expert insights and a review of the state of CHE, click here.

Try out either our interactive crossword or a static/non-interactive version below.

Interactive Crossword

This crossword was created with CrosswordLabs.com.

Static/Non-Interactive Crossword

Across

6. A non-systemic treatment for CHE that involves controlled light exposure

10. An oral JAK inhibitor studied for targeting both Th1 and Th2 in CHE treatment

11. An oral retinoid shown to outperform phototherapy in the ALPHA study for CHE

12. A topical pan-JAK inhibitor approved in the EU for CHE treatment

14. The excessive thickening of the outer skin layer, common in CHE lesions

15. A known adverse effect of long-term topical corticosteroid use in skin treatment

16. The proximal daily activity limitations score used in the HEIS measurement tool

Down

1. CHE often presents with more than 1 of these, complicating diagnosis and treatment

2. 1 in 5 patients attributed CHE to this kind of exposure or hazard

3. A descriptive term for the skin affected by CHE, often cracked too

4. Topical treatment with associated phobia and concerns over long-term skin damage

5. Patients with CHE may escalate to this level of therapy after failing topicals

7. (Abbreviation) A validated scale that measures the quality of life impact of CHE

8. A study evaluating real-world physician-reported outcomes of CHE management9. (Abbreviation) A class of drugs that block Janus kinase signaling and may be used off-label for CHE

13. A multinational study investigating the burden and prevalence of CHE

For answers to this week's puzzle, check out next week's edition of the Dermatology Times Sunday Crossword.

Answers from our May 18, 2025 puzzle: [Across: 1 - roflumilast; 5 - niacinamade; 6 - polyphenols; 11 - tralokinumab; 13 - antioxidants; Down: 2 - tapinarof; 3 - Type 2; 4 - comorbidity; 6 - psychosocial; 7 - ruxolitinib; 8 -avobenzone; 9 - infrared; 10 - stress; 12 - itch]